Paced Atrioventricular Delay Research Articles

Evaluation of ventricular pacing suppression algorithms in dual chamber pacemaker: Results of "LEADER" study.

There is limited research on the intra-individual efficacy of ventricular pacing minimization algorithms developed by Biotronik-the Ventricular Pace Suppression algorithm (VpS) and the Intrinsic Rhythm Support plus algorithm (IRSplus) (BIOTRONIK SE & Co. KG, Berlin, Germany). We performed a randomized pilot trial that evaluated the efficacy of two algorithms in patients with symptomatic sinus node dysfunction (SND) who received a dual-chamber pacemaker. The trial was conducted in 11 tertiary hospitals in South Korea. The patients were randomized to either the VpS or IRSplus algorithm group after a 3-month period of fixed atrioventricular (AV) delay. The primary outcome was the ventricular pacing percentage (Vp%) at each follow-up visit. The secondary outcomes were the occurrence of heart failure (HF) and atrial fibrillation (AF) during the study period. Data from 131 patients were analyzed. Initially, their average Vp% over 3 months with a fixed AV interval was 14.1 ± 19.4%. Patients were randomly assigned to VpS and IRSplus groups, with 66 and 65 in each. Algorithms reduced average Vp% to 4.0 ± 11.3% at 9 months and 6.7 ± 14.9% at 15 months. These algorithms were more effective for patients with paced AV delay (PAVD) ≤300 ms compared to those with PAVD >300 ms. Both algorithms were equally effective in reducing Vp%. Clinical AF or HF hospitalization was not observed during the study period. The VpS and IRSplus algorithms are effective and safe in minimizing unnecessary ventricular pacing in patients with SND.

AV synchrony maintained by a dual-chamber leadless pacemaker in real-world conditions

Abstract Background/Introduction A dual-chamber leadless pacemaker system has been developed to provide atrial and ventricular pacing and maintain atrioventricular (AV) synchrony. The device demonstrated an ability to maintain consistent AV synchrony in an in-clinic setting when tested through a series of postures and gaits under some programming restrictions. Assessing AV synchrony within real-world conditions is needed to understand the device’s performance under wider variations in activity and over a longer period. Purpose Assess a dual-chamber leadless pacemaker’s ability to maintain AV synchrony in an ambulatory environment of daily living under clinically driven programmed settings. Methods Implanted de novo subjects, who had at least 25% atrial pacing after 3-months post-implant, wore a 12-lead Holter monitor for a minimum of 24 hours during normal daily activities and completed a symptom diary. Devices were programmed to a dual chamber pacing mode and clinically appropriate settings then interrogated pre- and post-assessment. An independent Core Laboratory evaluated AV Synchrony, based on a configurable sampling window approach at repeated intervals, and defined synchronous cycles based on whether PR intervals fell within a 50 ms margin of the programmed Paced AV Delay. Results Among the 50 subjects who were administered the assessment, 48 of their Holters were analyzable (mean age 71.4 ± 10.9 years; 66.7% male), and 47 subjects had paired device interrogation data available. The analyzable population was predominantly indicated for sinus node dysfunction (83.3%) with a minority indicated for AV block (16.7%). The mean ± standard deviation of the programmed paced AV delay was 260.0 ± 47.6 ms, and mean PR interval was 241.4 ± 35.1 ms. An atrial paced beat and ventricular paced beat were each present in 69.5% and 22.5% of the evaluable cardiac cycles in the population, respectively. Mean AV Synchrony was maintained above 97% (95% CI: 95.5, 98.8) in the entire cohort and was sustained at high rates within each sub-population. Device metrics that diagnose the rate of directional implant-to-implant (i2i) communication also confirmed device data average throughput rates above 90% (Picture 1). There were no reported episodes of oversensing, undersensing, loss of capture, or pauses. Conclusion Among subjects with standard pacemaker indications, the dual-chamber leadless pacemaker system maintains very high rates of AV synchrony, exceeding i2i throughput, within real-world conditions utilizing clinically appropriate programmed settings.AV Synchrony and i2i by Indication

Abstract 14310: Evaluation of Ventricular Pacing Suppression Algorithmsin Dual Chamber Pacemaker: Results of 'Leader' Study

Introduction: Several algorithms have been proposed to reduce unnecessary right ventricular (RV) pacing, and their operations are based on two different mechanisms: (i) atrioventricular (AV) hysteresis (AVH) and (ii) DDD to AAI pacing mode change. Hypothesis: The purpose of our study was to evaluate the efficacy and safety of two ventricular pacing suppression algorithms: Intrinsic Rhythm Support (IRS) plus algorithm (using AVH, IRSplus) and VP suppression (DDD to AAI mode change) algorithm (VpS). Methods: This was a multicenter, randomized study conducted in 11 tertiary hospitals in South Korea. Patients with sinus node dysfunction and receiving dual-chamber permanent pacemaker implantation were included in this study. After the implantation, patients maintained a fixed AV interval for three months. The AV conduction time was determined as the "atrial pacing to ventricular sensing interval" observed from the marker channel during the PPM implantation was set as the sensed AV delay. The paced AV delay was set to be the sensed AV delay+30ms. Subsequently, patients were randomly assigned to either the VpS or IRSplus algorithm group and were followed for 12 months with assessments every 6 months. Results: A total of 118 patients were enrolled, and the total RV pacing percentage (Vp%) of the patients during the 3 months with a fixed AV interval was 10.9±16.0 on average. They were randomly assigned to VpS and IRSplus groups, with 62 and 56 patients in each group. Six months later, the average Vp% was 14.6±18.8 to 2.7±6.0, P<0.001 and 6.8±10.9 to 1.1±4.0, P<0.001 for the VpS and IRSplus groups, respectively. This trend was maintained for additional 6 months (VpS group: 4.6±9.5; IRSplus group: 1.2±3.8). The effects of algorithms were more pronounced in groups with an intrinsic PR interval of < 200ms, and the IRSplus showed better efficacy (Figure). Conclusions: The two ventricular pacing suppression algorithms were effective in reducing Vp% compared to the fixed AV interval.

Atrioventricular optimization in cardiac resynchronization therapy with quadripolar leads: should we optimize every pacing configuration including multi-point pacing?

This study aims to define an atrioventricular (AV) delay optimization method for cardiac resynchronization therapy (CRT) with a quadripolar left ventricular (LV) lead based on intrinsic conduction intervals. Heart failure patients with a left bundle branch block underwent CRT implantation with a quadripolar LV lead. Invasive LV pressure-volume loops were recorded during four biventricular and three multi-point pacing (MPP) settings, using four patient-specific paced AV delays. Haemodynamic response was defined as change in stroke work (Δ%SW) compared to intrinsic rhythm and was related to the following conduction intervals: right atrial pacing to right ventricular sensing interval (RAp-RVs), Q to LV sensing interval normalized to QRS duration (QLV/QRSd), PR-interval, and P-wave duration. In 44 patients, the largest Δ%SW (104 ± 76%) occurred at a paced AV delay of 128 ± 32 ms, at 47 ± 9% of RAp-RVs. Optimal AV delay of biventricular pacing (126 ± 26 ms) did not differ from MPP (126 ± 21 ms, P = 0.29). Intra-class correlation coefficient between optimal AV delays of different pacing configurations was 0.64 (0.45-0.78, P < 0.001). Although not statistically significant, Δ%SW at 50% of RAp-RVs (98 ± 74%) was closer to the maximal achievable Δ%SW increase than a fixed interval of 120 ms (96 ± 73%, P = 0.60). RAp-RVs, QLV/QRSd, PR interval, and P-wave duration were associated with the optimal AV delay in univariate analysis, but only RAp-RVs remained significantly associated in multivariate analysis (R = 0.69). The AV delay that provides highest haemodynamic response is similar for various LV pacing configurations and for MPP. An AV delay ∼50% of RAp-RVs creates an acute haemodynamic response close to the maximal patient-specific response.

Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block

Controversy remains regarding the use of cardiac resynchronization therapy (CRT) in patients with heart failure with right bundle branch block (RBBB) and reduced left ventricular (LV) ejection fraction. Moreover, little is known about acute hemodynamic changes with CRT in this subgroup as compared with patients with left bundle branch block (LBBB). The purpose of this study was to evaluate the acute biventricular hemodynamic response of CRT and other pacing configurations, including the effects of atrioventricular (AV) delay and atrial pacing, to understand the effects of CRT in RBBB. Forty patients (9 with RBBB and 31 with LBBB) undergoing CRT implantation underwent temporary pacing with varying configurations and AV delay. The acute hemodynamic response was assessed via invasive measurements of dP/dtmax (maximal rate of change in pressure) in the left ventricle (LV) as well as the right ventricle (RV) in patients with RBBB. Patients with LBBB had a greater LV dP/dtmax response to CRT than did patients with RBBB. In patients with RBBB, single- or dual-site RV pacing configurations resulted in greater increases in RV dP/dtmax than did biventricular pacing. Optimal AV delays that maximized RV dP/dtmax were shorter than optimal AV delays for LV dP/dtmax. Furthermore, AV delays chosen to maximize improvement in RV dP/dtmax frequently resulted in negative effects on LV dP/dtmax. These findings demonstrate a complex relationship between pacing configuration, AV delay, and hemodynamic responses. The biventricular hemodynamic response in patients with heart failure with RBBB might be improved by optimizing pacing modalities and AV delays. This may be particularly important in patients with diseases in whom RV failure predominates, such as patients with pulmonary hypertension and LV assist device.

Rationale and evidence for the development of a durable device-based cardiac neuromodulation therapy for hypertension

We assessed the feasibility of achieving acute, sustained blood pressure reductions through the use of cardiac pacing algorithms delivered via standard dual-chamber pacing based on introducing short atrio-ventricular (AV) delays (SAVD). Eighteen hypertensive subjects (57.3 ± 9.8 years old; 10 male and 8 female) with average initial systolic and diastolic blood pressures of 151.2 ± 17.6/92.2 ± 12.7 mmHg already scheduled to undergo an invasive electrophysiology procedure were included in this study. Pacing sequences were applied for ∼1-minute intervals with AV delays of 80, 40, 20 and 2 ms, while making high fidelity blood pressure measurements. Average reductions of 19.6 ± 7.7 mmHg in systolic pressure and 4.3 ± 3.8 mmHg in diastolic pressure (P < .001 each) were demonstrated with 2 ms AV delay pacing. Initial SBP reductions were followed by rebound effects which diminished the SBP reducing effects of SAVD pacing, likely due to baroceptor activation causing increased peripheral resistance. This effect was eliminated by intermittent introduction of longer AV delay pacing which modulated the baroreflexes. These findings provide the rationale and evidence underlying recent data showing significant and long-term blood pressure reductions in response to this cardiac neuromodulation therapy in hypertensive patients despite medical therapy.

Short atrioventricular delay pacing therapy in young and old patients with hypertrophic obstructive cardiomyopathy: good long-term results and a low need for reinterventions.

AimsExamination of long-term results following different treatments in hypertrophic obstructive cardiomyopathy (HOCM) in a complete geographical cohort.Methods and resultsHOCM patients attending during 2002–13 in all 10 hospitals in the West Götaland Region, Sweden, were identified (n = 251), follow-up 14.4 (±8.9) years (mean ± SD), 121 managed medically, 42 treated with myectomy and 88 with short atrioventricular (AV) delay pacing as first interventional procedure. Post-intervention follow-up was 12.9 ± 8.7 years and 12.2 ± 5.0 years, respectively. Both intervention treatments improved New York Heart Association (NYHA) class and outflow gradients significantly. Patients treated with pacing were older (median age 64 vs. 43 years, P < 0.001). Freedom from disease-related death post-procedure at 5, 10, and 20 years were 93%, 80%, 56% vs. 93%, 93%, 57% in pacing and myectomy groups, respectively (log-rank P = 0.43). Survival after diagnosis was not different in patients just treated conservatively (P = 0.51 pacing/conservative; P = 0.39 myectomy/conservative). Reintervention for outflow gradients in patients ≥18 years at procedure occurred in 3.5% in pacing group and 15.6% in myectomy group (P = 0.007). Pacing therapy was equally effective in patients aged 13–64 years (n = 44), as in patients ≥65 years (n = 44): resting gradient pre-procedure and at last follow-up were median (IQR) 65 (71) and 12 (20) mmHg for <65 year-olds (P < 0.001), and 75 (64) and 14 (38) mmHg, respectively, for ≥65 year-olds (P < 0.001). New York Heart Association class improved significantly in both age ranges to 1.6 ± 0.6 and 1.8 ± 0.7, respectively (P < 0.001; P < 0.001).ConclusionShort AV delay pacing provided lasting satisfactory relief of symptoms and outflow obstruction in the majority of patients, with low risk of requiring reintervention. Our findings support the view that pacing therapy should be considered a valid option to treat patients with HOCM.

P1526Interventricular delay and left ventricular delay in right ventricular pacemaker pacing before upgrading to biventricular pacing

Background: Cardiac resynchronization therapy (CRT) with biventricular (BV) pacing is an established therapy for heart failure (HF) patients (P) with sinus rhythm, reduced left ventricular (LV) ejection fraction (EF) and electrical ventricular desynchronization. The aim of the study was to evaluate electrical interventricular delay (IVD) and left ventricular delay (LVD) in right ventricular (RV) pacemaker pacing before upgrading to CRT BV pacing. Methods: HF P (n=11, age 69.0 ± 7.9 years, 1 female, 10 males) with DDD pacemaker (n=10), DDD defibrillator (n=1), RV pacing, New York Heart Association (NYHA) class 3.0 ± 0.2 and 24.5 ± 4.9 % LVEF were measured by surface ECG and transesophageal bipolar LV ECG before upgrading to CRT defibrillator (n=8) and CRT pacemaker (n=3). IVD was measured between onset of QRS in the surface ECG and onset of LV signal in the transesophageal ECG. LVD was measured between onset and offset of LV signal in the transesophageal ECG. CRT atrioventricular (AV) and BV pacing delay were optimized by impedance cardiography. Results: Interventricular and intraventricular desynchronization in RV pacemaker pacing were 228.2 ± 44.8 ms QRS duration, 86.5 ± 32.8ms IVD, 94.4 ± 23.8ms LVD, 2.6 ± 0.8 QRS-IVD-ratio with correlation between IVD and QRS-IVD-ratio (r=-0.668 P=0.0248) and 2.3 ± 0.7 QRS-LVD-ratio. The LVEF-IVD-ratio was 0.3 ± 0.1 with correlation between IVD and LVEF-IVD-ratio (r=-0.8063 P=0.00272) and with correlation between QRS duration and LVEF-IVD-ratio (r=-0.7251 P=0.01157). Optimal sensing and pacing AV delay were 128.3 ± 24.8 ms AV delay after atrial sensing (n=6) and 173.3 ± 40.4 ms AV delay after atrial pacing (n=3). Optimal BV pacing delay was -4.3 ± 11.3 ms between LV and RV pacing (n=7). During 30.4 ± 29.6 month CRT follow-up, the NYHA class improved from 3.1 ± 0.2 to 2.2 ± 0.3. Conclusions: Transesophageal electrical IVD and LVD in RV pacemaker pacing may be additional useful ventricular desynchronization parameters to improve P selection for upgrading RV pacemaker pacing to CRT BV pacing.

Cardiac resynchronization therapy beyond nominal settings: who needs individual programming of the atrioventricular and interventricular delay?

This study aimed to determine the additional acute haemodynamic effect of atrioventricular (AV) and interventricular (VV) delay optimization compared with current nominal cardiac resynchronization therapy (CRT) device settings, and to explore whether clinical characteristics correlate to the effect of optimization. Fifty CRT patients were prospectively enrolled. The optimal AV and VV delays were guided by relative improvement in maximum rate of left ventricular (LV) pressure rise (%dP/dt(max)). A significant improvement in %dP/dt(max) was obtained by optimization in 23-33% (sensed AV delay), 32-57% (paced AV delay), and 45% of patients (VV delay). Adjustment of the device nominal VV delay from 0 to 40 ms LV pre-activation would diminish the proportion of patients with additional effect of individual optimization from 45 to 15%. Heart failure aetiology [ischaemic 2 ± 2 vs. non-ischaemic 1 ± 1 percentage points (PP) %dP/dt(max), P= 0.013], gender (men 2 ± 2 vs. women 1 ± 1 PP %dP/dt(max), P= 0.012) and intrinsic PR interval (R= 0.49, P= 0.002) correlated to the degree of effect of AV delay optimization. Women yielded more effect of VV delay optimization (4 ± 3 vs. 2 ± 1 PP %dP/dt(max), P= 0.026). Compared with the best of the currently available device nominal AV and VV delays, 23-45% of CRT patients can yield additional acute haemodynamic effect by individual optimization of the delays. A new nominal VV delay of 40 ms LV pre-activation is recommended. Male gender, ischaemic aetiology, and longer PR interval are associated with a larger effect of individual optimization.

Pacemaker “Dysfunction” Treated by Radiofrequency Ablation

A 68-year-old female with a history of paroxysmal atrial fibrillation and complete atrioventricular (AV) block was referred for palpitations and suspicion of pacemaker dysfunction (model Philos II DR-T, Biotronik, Berlin, Germany). Baseline electrocardiogram (ECG) showed a dual-chamber pacemaker with an inappropriate behavior (Fig. 1, Panel A). Pacemaker programmed parameters were as follows: pacing mode DDD-R; basic rate 60 beats per minute (bpm); upper rate 130 bpm; dynamic paced AV delay 180/140 ms; dynamic sensed AV delay 135/95 ms; AV safety window 100 ms; atrial sensitivity 0.5 mV (bipolar); ventricular sensitivity 2.5 mV (bipolar); atrial and ventricular pulse amplitude and width 3.6 V and 0.40 ms, respectively (both unipolar). Pacemaker testing showed the following results: battery impedance 0.3 k ; sensed P wave 3 mV, sensed R wave 25 mV; atrial and ventricular pacing thresholds 0.6 and 0.4 V, respectively; atrial and ventricular lead impedances 442 and 560 , respectively (stable). Testing of the atrial pacing threshold in AAI mode at 70 bpm allowed the diagnosis to be made (Fig. 1, Panel B). What is the mechanism of the pacemaker “dysfunction”? How can it be solved?

Erroneous automatic pacemaker arrhythmia diagnosis: Is it malfunction or a design limitation?

A 76-year-old man received a St Jude Medical's Zephyr XL DR pacemaker 3 years ago for symptomatic second-degree atrioventricular (AV) block with bradycardia. The parameters when Figure 1 was recorded were as follows: mode DDDR, lower rate 55 ppm, upper tracking rate 130 ppm, paced AV delay 170 ms, sensed AV delay 120 ms (shortest AV delay 100 ms), postventricular atrial refractory period (PVARP) 275 ms, rate adaptive shortest duration 170 ms, postventricular atrial blanking period 100 ms, and atrial tachycardia detection rate (ATDI) 180 bpm (interval = 333 ms). By design, automatic mode switching (AMS) entry and high atrial trigger were automatically suspended by programming atrial tachycardia/atrial fibrillation (AT/AF) detection. At the time of follow-up, the device indicated that it had recorded 10 episodes of AT/AF over a period of 4 months. The AT/AF episodes lasted no longer than 6 minutes. The highest recorded rate of the AT/AF episodes was 284 bpm. No other important arrhythmias were recorded. Figure 1 is representative of all the recorded episodes labeled AT/AF by the pacemaker.

Atrial Threshold Variability: Implications for Automatic Atrial Stimulation Algorithms

Automatic management of atrial stimulation by verification of atrial threshold (ACM) has recently been made feasible. We investigated circadian atrial threshold variability over the long term and the predictors of successful automatic atrial threshold measurement, in order to provide practical clues for programming ACM features, in such a way as to achieve daily threshold verification and > 99% effective atrial stimulation. Six daily attempts to measure atrial threshold were programmed in patients receiving an EnPulse pacemaker (Medtronic Inc., Minneapolis, MN, USA). Atrioventricular (AV) conduction was maximized by programming Search AV+ (SAV+) to a resting Paced AV delay = 400 ms in the first month, and 600 ms thereafter. Seventy-six patients had a median follow-up of 12 months. Median ACM success was 77%. Concordance between automatically and manually measured thresholds was observed during the entire follow-up (Rho = 0.82, P < 0.001). Daily variability in atrial threshold was < 0.5 V in > 94% of measurements in the first trimester after implantation, and < 0.5 V in > 99% of measurements thereafter, as well as any time after pacemaker replacement. Atrial threshold was measured on 86% of days: the predictors of ACM failure were AV block (AVB), high%Atrial pacing, and atrial fibrillation. Programming SAV+ to achieve 600 ms resting Paced AV decreased%Vpacing in patients with normal AV conduction and first-degree AVB, improving the ability to detect atrial threshold. The reliability of ACM is high over a long follow-up. On the basis of atrial threshold variability, a practical approach to ACM programming should be two daily atrial threshold measurements in patients with normal AV conduction and%Ap < or = 40%, or with normal sinus activity and AVB, whereas 3-4 measurements should be recommended in patients with first-degree AVB and%Ap > 40% or with recurrent atrial fibrillation and AVB. The lowest adapted stimulation output should achieve at least threshold +1 V in the first trimester after implantation, then threshold +0.5 V thereafter, in order to achieve > 99.5% effective atrial stimulation.

Interatrial Conduction Measured During Biventricular Pacemaker Implantation Accurately Predicts Optimal Paced Atrioventricular Intervals

Optimizing atrioventricular (AV) delay during biventricular (BiV) pacemaker implantation can require substantial resources. Hence, a simpler method is desirable. We hypothesized that interatrial conduction time (IACT), measured at the time of BiV device implant, could be a surrogate value for the optimal AV delay. This study determined the relationship between paced IACT and the optimal paced AV delay (PAV), as determined by echocardiography. Consecutive subjects (N = 25; age = 66 +/- 10 years; M/F: 17/8) undergoing BiV pacemaker implantation and in sinus rhythm were included. Cannulation of the coronary sinus (CS) was at the operator's discretion. A quadripolar electrophysiology catheter was inserted via the guiding sheath into the inferiolateral CS to measure left atrial depolarization. The IACT was calculated as the interval between right atrial stimulation artifact and earliest deflection on the coronary sinus catheter electrogram. Subsequently, during atrial pacing the PAV was determined using transmitral pulsed wave Doppler echocardiography (iterative method). The relationship between paced IACT and PAV was then determined. The mean +/- SD paced IACT and PAV were 126 +/- 25 msec and 157 +/- 23 msec, respectively. There was a strong positive correlation between the paced IACT and PAV (r = 0.73, P < 0.001). The equation describing the relationship was PAV = 0.68 * (IACT + 104) msec. The paced IACT has a strong correlation with the echo derived optimal PAV. This method may be used to program PAV intervals without need for echocardiography in patients undergoing BiV pacemaker implantation.

Hemodynamic comparison of ventricular pacing, atrioventricular sequential pacing, and atrial synchronous ventricular pacing using radionuclide ventriculography

To assess the hemodynamic effects of physiologic pacing, 13 patients with DDD pacemakers who had varying degrees of atrioventricular (AV) block were studied with radionuclide ventriculography during VVI, DVI and VDD modes. Radionuclide ventriculography was performed with patient in the supine position at rest 5 to 10 minutes after the pacing mode and AV delay were changed. The AV delays selected were short (mean 147 ± 4.8 ms) and long (mean 197 ± 4.8 ms), with a constant difference of 50 ms. During VVI, 6 patients (group 1) had a left ventricular ejection fraction of 40% or less (mean 22 ± 11) and 7 patients (group 2) had an ejection fraction of more than 40% (mean 59 ± 11). Comparisons of ejection fraction, end-diastolic volume and cardiac index between VVI and both modes of AV pacing (VDD and DVI) and between long and short AV delays led to the following conclusions: DVI or VDD pacing produces more beneficial hemodynamic effects than VVI, and these effects are more pronounced in patients with low ejection fraction if longer AV delay is used. The VDD mode significantly improves ventricular function over the DVI mode in patients with an ejection fraction of more than 40% independent of heart rate. Longer AV delay is essential in patients with an ejection fraction of 40% or less to improve ventricular function with physiologic pacing.